MedAvail Holdings, Inc.

As of June 30, 2023, MedAvail Holdings, Inc. carries a market capitalization of 19.78M, placing it among publicly traded companies globally. Its enterprise value stands at 7.68M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2023, MedAvail Holdings, Inc. has 1.61M shares outstanding.

These figures are as of June 30, 2023. The price-to-sales ratio is 0.85, and the price-to-book ratio stands at 0.86.

These figures are as of June 30, 2023. The EV/Sales ratio of 0.32 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 7.68M versus a market cap of 19.78M, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2023, MedAvail Holdings, Inc. maintains a current ratio of 6.51, meaning it holds 6.5x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 9.82, indicating elevated leverage, while an interest coverage ratio of -28.19 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2023, MedAvail Holdings, Inc. posted a negative return on equity (ROE) of -164.77, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -111.18, reflecting losses generated across the asset base. The company generates approximately 84,825.62 in revenue per employee across its workforce of 281.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 2.84 indicates how many times MedAvail Holdings, Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.

As of the close on September 28, 2026, MedAvail Holdings, Inc.'s stock has gained approximately 0.00% over the past 52 weeks. The 50-day moving average sits at 0.32, while the 200-day moving average is 4.72.

Over the twelve months ended June 30, 2023, MedAvail Holdings, Inc. generated 23.84M in revenue and converted that into -46.00M in net income, yielding earnings per share of -24.78. EBITDA reached -26.98M, while operating income came in at -31.70M.

As of June 30, 2023, MedAvail Holdings, Inc. holds 14.36M in cash and equivalents against 2.26M in total debt, resulting in a net debt position of -12.85M. Total book value stands at 23.05M, with working capital of 22.89M providing operational flexibility.

MedAvail Holdings, Inc. produced -31.54M in operating cash flow over the twelve months ended June 30, 2023. After subtracting -692,000.00 in capital expenditures, free cash flow totaled -32.23M - equivalent to -19.51 per share.

Over the twelve months ended June 30, 2023, MedAvail Holdings, Inc. posted a gross margin of 6.72, reflecting its pricing power and cost economics. The operating margin of -132.99 and net profit margin of -192.97 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2023. Free cash flow yield is negative at -159.23: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -87.48, meaning MedAvail Holdings, Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

MedAvail Holdings, Inc.'s most recent stock split took place on August 1, 2023 with a 50:1 split ratio.

As of June 30, 2023, MedAvail Holdings, Inc. has an Altman Z-Score of -12.67, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.